Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
News|Videos|October 7, 2025
Lawrence Eichenfield, MD; and Rocco Serrao, MD, react to roflumilast approval for pediatric atopic dermatitis
Author(s)Lawrence Eichenfield, MD, Rocco Serrao, MD
Fact checked by: Joshua Fitch, Senior Editor
A pair of roflumilast clinical trial investigators react to the FDA approval of the 0.05% formulation to treat atopic dermatitis in children aged 2 to 5 years.
Advertisement
Advertisement
A newly approved nonsteroidal topical agent offers pediatricians and caregivers an additional treatment option for young children with atopic dermatitis (AD). Lawrence Eichenfield, MD; and Rocco Serrao, MD, discussed the expanded
Related to this article
Real-world claims show dupilumab was tied to a 33%-52% lower risk of atopic march progression vs systemic corticosteroids in children with AD.
Once-daily roflumilast cream 0.05% was well tolerated in infants 3 to <24 months with AD, with 34.4% reaching vIGA-AD success at week 4.
At AAP 2026, Peter Lio, MD, discussed distinguishing allergic and inflammatory skin conditions and when pediatricians should seek specialty care.
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.
The FDA approved insulin icodec-abae for children 10+ with T2D, based on adult ONWARDS data and a single-dose pediatric pharmacokinetic study.
Christina Boull, MD, explains how pediatricians can recognize dermatologic conditions in darker skin tones and address pigment changes and treatment gaps.
Advertisement
Advertisement